Table VI.
Haplotype distribution and formation between patients and controls for association of haplotype blocks with non-small cell lung cancer risk.
| Frequency (%) | ||||||
|---|---|---|---|---|---|---|
| Block | Loci | Cases/controls | Haplotype | Cases | Controls | P-value |
| Block 1 | rs312009 and 3120015 | NSCLC patients | CG | 60.2 | 60.0 | 0.93 |
| Controls | TC | 24.4 | 24.5 | 0.98 | ||
| CC | 15.4 | 15.5 | 0.94 | |||
| Male NSCLC patients | CG | 60.1 | 60.3 | 0.96 | ||
| Male controls | TC | 25.1 | 24.8 | 0.89 | ||
| CC | 14.7 | 14.9 | 0.92 | |||
| ADC patients | CG | 58.9 | 60.0 | 0.65 | ||
| Controls | TC | 25.8 | 24.4 | 0.52 | ||
| CC | 15.3 | 15.5 | 0.88 | |||
| Male ADC patients | CG | 57.9 | 60.2 | 0.49 | ||
| Male controls | TC | 27.5 | 24.7 | 0.34 | ||
| CC | 14.6 | 14.9 | 0.89 | |||
| Female NSCLC patients | CG | 60.3 | 59.8 | 0.88 | ||
| Female controls | TC | 22.7 | 24.0 | 0.68 | ||
| CC | 17.0 | 16.2 | 0.78 | |||
| Female ADC patients | CG | 60.2 | 59.8 | 0.91 | ||
| Female controls | TC | 23.6 | 24.0 | 0.91 | ||
| CC | 16.2 | 16.2 | 0.98 | |||
| Block 2 | rs491347, rs1784235, and rs607887 | NSCLC patients | TTC | 76.6 | 74.6 | 0.28 |
| Controls | CCT | 18.3 | 19.9 | 0.37 | ||
| TTT | 4.3 | 4.9 | 0.53 | |||
| Male NSCLC patients | TTC | 76.1 | 72.2 | 0.12 | ||
| Male controls | CCT | 18.8 | 22.8 | 0.09 | ||
| TTT | 4.0 | 4.5 | 0.70 | |||
| ADC patients | TTC | 76.6 | 74.6 | 0.36 | ||
| Controls | CCT | 18.3 | 19.9 | 0.41 | ||
| TTT | 4.4 | 4.9 | 0.62 | |||
| Male ADC patients | TTC | 75.6 | 72.2 | 0.25 | ||
| Male controls | CCT | 19.5 | 22.7 | 0.25 | ||
| TTT | 3.5 | 4.5 | 0.46 | |||
| SCC patients | TTC | 76.8 | 74.6 | 0.42 | ||
| Controls | CCT | 18.4 | 19.9 | 0.56 | ||
| TTT | 4.2 | 4.9 | 0.58 | |||
| Male SCC patients | TTC | 77.0 | 72.2 | 0.12 | ||
| Male controls | CCT | 18.0 | 22.8 | 0.10 | ||
| TTT | 4.4 | 4.5 | 0.95 | |||
| Block 3 | rs491347, rs1784235, rs607887 and rs3736228 | Female NSCLC patients | TTCC | 77.6 | 77.1 | 0.85 |
| Female controls | CCTT | 16.3 | 16.7 | 0.90 | ||
| TTTC | 4.0 | 4.2 | 0.92 | |||
| TTTT | 1.0 | 1.3 | 0.75 | |||
| Female ADC patients | TTCC | 78.1 | 77.1 | 0.73 | ||
| Female controls | CCTT | 15.8 | 16.7 | 0.77 | ||
| TTTC | 4.3 | 4.2 | 0.96 | |||
| TTTT | 1.1 | 1.3 | 0.81 | |||
| Female SCC patients | TTCC | 68.7 | 77.1 | 0.43 | ||
| Female controls | CCTT | 25.0 | 16.7 | 0.38 | ||
| TTTC | 0.0 | 4.2 | 0.40 | |||
| TTTT | 0.0 | 1.3 | 0.65 | |||
| Block 4 | rs312009, rs3120014 and rs3120015 | SCC patients | CGC | 57.6 | 52.4 | 0.09 |
| Controls | TCG | 21.6 | 24.4 | 0.29 | ||
| CCG | 15.0 | 14.9 | 0.94 | |||
| CGG | 5.1 | 7.7 | 0.11 | |||
| Male SCC patients | CGC | 58.0 | 52.3 | 0.10 | ||
| Male controls | TCG | 22.3 | 24.7 | 0.44 | ||
| CCG | 14.6 | 24.5 | 0.97 | |||
| CGG | 4.7 | 7.9 | 0.07 | |||
| Female SCC patients | CGC | 49.9 | 52.4 | 0.84 | ||
| Female controls | TCG | 6.2 | 24.0 | 0.10 | ||
| CCG | 24.9 | 15.3 | 0.30 | |||
| CGG | 12.6 | 7.4 | 0.45 | |||
| CCC | 6.4 | 0.9 | 0.04 | |||
NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma.